FERM and PDZ domain containing 4Genealiases: MRX104 · PDZD10 · PDZK10 · XLID104
Q-omics provides the consensus-scored FRMPD4 profile across patient tissues and cancer cell-line models. FRMPD4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FRMPD4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, FRMPD4 RNA expression shows 13,652 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, COAD, and THYM as cancer lineages where FRMPD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMPD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMPD4 survival associations across molecular data types. FRMPD4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMPD4 RNA expression–survival associations across cancer types. High FRMPD4 expression shows unfavorable associations in LUSC, KIRP and UVM, but favorable associations in MESO, SKCM and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FRMPD4 RNA expression.
This table summarizes FRMPD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FRMPD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMPD4 shows lower tumor expression in COAD, BRCA, UCEC, LUAD and READ and higher tumor expression in KICH. The COAD box plot shows higher FRMPD4 RNA expression in normal versus tumor tissue (log2 FC = −0.439, t-test p < 0.001).
This table shows molecular features associated with FRMPD4 in patient tissues and cancer cell lines. In patient samples, FRMPD4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMPD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
